A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Dermatology"
DOI: 10.1111/bjd.15354
Abstract: Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death (PD)‐1 receptor. Common cutaneous adverse side‐effects of PD‐1 inhibitors include maculopapular rash, pruritus, vitiligo and lichenoid skin and mucosal reactions. Here we describe… read more here.
Keywords: skin lesions; report disappearing; pigmented skin; metastatic melanoma ... See more keywords